Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4.8% – Should You Sell?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) fell 4.8% during mid-day trading on Wednesday . The stock traded as low as $27.57 and last traded at $27.60. 844,801 shares were traded during trading, a decline of 55% from the average session volume of 1,890,824 shares. The stock had previously closed at $28.99.

Analysts Set New Price Targets

Several equities research analysts have weighed in on APLS shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $25.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, November 4th. Citigroup decreased their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. HC Wainwright reduced their price objective on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Wedbush upped their target price on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $49.94.

Apellis Pharmaceuticals Trading Up 2.6 %

The firm’s fifty day moving average is $29.06 and its two-hundred day moving average is $35.79. The firm has a market capitalization of $3.54 billion, a PE ratio of -13.80 and a beta of 0.87. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the business earned ($1.17) earnings per share. Apellis Pharmaceuticals’s revenue was up 78.3% on a year-over-year basis. On average, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares in the company, valued at $3,623,000. The trade was a 27.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 6.80% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in APLS. Envestnet Asset Management Inc. increased its stake in Apellis Pharmaceuticals by 42.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after acquiring an additional 39,931 shares during the last quarter. Profund Advisors LLC increased its position in shares of Apellis Pharmaceuticals by 90.7% in the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock worth $1,648,000 after purchasing an additional 20,435 shares during the last quarter. Algert Global LLC raised its stake in Apellis Pharmaceuticals by 137.8% in the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares in the last quarter. Toronto Dominion Bank bought a new stake in Apellis Pharmaceuticals during the first quarter valued at approximately $588,000. Finally, Edgestream Partners L.P. grew its stake in Apellis Pharmaceuticals by 240.4% in the 2nd quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock worth $2,093,000 after buying an additional 38,541 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).